Ignite Creation Date:
2024-05-06 @ 7:47 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02607592
Status:
UNKNOWN
Last Update Posted:
2022-02-25
First Post:
2015-11-16
Brief Title:
A Prospective Multi-center Phase III Randomized Controlled Trial
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Nedaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced AdenocarcinomaA Prospective Multi-center Phase III Randomized Controlled Trial
Status:
UNKNOWN
Status Verified Date:
2022-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NACA
Brief Summary:
The purpose of this study is to investigate the PFS ORR OS and overall toxicity valueOTVon advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None